Guidelines
Staphylococcus aureus Bacteremia

Staphylococcus aureus Bacteremia

ID consult is required and is associated with improved patient outcomes

  • S. aureus bacteremia is associated with significant morbidity and mortality (mortality up to 20-40%)
  • It is essential to control the source of infection and initiate urgent treatment
  • Isolation of S. aureus in the blood should NEVER be considered a contaminant

Microbiology

  • Evidence of MRSA infection elsewhere
  • Nasal colonization with MRSA
  • Recent hospitalization
  • Hemodialysis
  • Injection drug use
  • HIV infection
  • Recent antibiotic use (especially IV in the last 3 months)
  • Sharing sports equipment/contact sports

Additional Information

Guideline originally sourced from Saskatchewan Health Authority - Saskatoon Area and adapted by Joseph Brant Hospital

  • Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011 Aug 1;53(3):319]. Clin Infect Dis. 2011;52(3):e18-e55.

  • The Johns Hopkins University (2020) John Hopkins ABX Guide (1.27) [Mobile App] Retrieved from: www.hopkinsguides.com

  • Antimicrobial Therapy Inc (2020) The Sanford Guide (4.2) [Mobile App] Retrieved from: www.sanfordguide.com/

  • Approved June 2020
  • Revised March 2021